BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37832553)

  • 1. Co-op CARs for targeting acute myeloid leukemia.
    Kondo T; Taylor N
    Cancer Cell; 2023 Nov; 41(11):1841-1843. PubMed ID: 37832553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative CAR targeting to selectively eliminate AML and minimize escape.
    Haubner S; Mansilla-Soto J; Nataraj S; Kogel F; Chang Q; de Stanchina E; Lopez M; Ng MR; Fraser K; Subklewe M; Park JH; Wang X; Rivière I; Sadelain M
    Cancer Cell; 2023 Nov; 41(11):1871-1891.e6. PubMed ID: 37802054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
    Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
    Lynn RC; Poussin M; Kalota A; Feng Y; Low PS; Dimitrov DS; Powell DJ
    Blood; 2015 May; 125(22):3466-76. PubMed ID: 25887778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
    Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
    Pratap S; Zhao ZJ
    Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
    Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo.
    Sun L; Jiang G; Ng YY; Xiao L; Du Z; Wang S; Zhu J
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10189-10201. PubMed ID: 37270461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
    Tashiro H; Sauer T; Shum T; Parikh K; Mamonkin M; Omer B; Rouce RH; Lulla P; Rooney CM; Gottschalk S; Brenner MK
    Mol Ther; 2017 Sep; 25(9):2202-2213. PubMed ID: 28676343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
    Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
    Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
    PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
    Gu B; Chu J; Wu D
    Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.